Bulletin of Experimental Biology and Medicine

, Volume 121, Issue 1, pp 44–47 | Cite as

Potentiation and acceleration effects in combined administration of tissue plasminogen activator and fibrinogen-modified urokinase in dogs with modeled venous thrombosis

  • A. V. Maksimenko
  • E. G. Tishchenko
  • M. L. Petrova
  • V. L. Golubykh
Biophysics and Biochemistry

Abstract

Combined administration of tissue plasminogen activator and a urokinase-fibrinogen covalent conjugate is studied using modeled venous thrombosis in dogs. In comparison with the effect of the individual preparations the thrombolytic effect was potentiated when intravenous bolus injection of 1 mg tissue plasminogen activator followed by a 2-hour infusion of 4 mg of this preparation was combined with bolus injection of 25,000 IU urokinase-fibrinogen covalent conjugate 15 min after the first bolus. Potentiation and acceleration of thrombolysis were attained with the same scheme when tissue plasminogen activator was administered in a dose of 1 mg for both bolus and infusion and combined with 250,000 IU of fibrinogen-modified urokinase.

Key Words

tissue plasminogen activator urokinase-fibrinogen covalent conjugate venous thrombosis combined thrombolytic activity potentiation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. V. Maksimenko,Zh. Vsesoyuz. Khim. Obshchestva im. D. I. Mendeleeva,32, No 5, 541–547 (1987).Google Scholar
  2. 2.
    A. V. Maksimenko,Khim.-Farm. Zh.,28, No 5, 4–11 (1994).Google Scholar
  3. 3.
    A. V. Maksimenko, —Ibid., No 12, 3–13.Google Scholar
  4. 4.
    A. V. Maksimenko,Molek. Biol.,28, No 1, 38–60 (1995).Google Scholar
  5. 5.
    A. V. Maksimenko, M. B. Samarenko, A. D. Petrov,et al., Khim.-Farm. Zh.,24, No 2, 117–119 (1990).Google Scholar
  6. 6.
    D. Collen, H. R. Lijnen, and H. K. Gold,Prog. Cardiovasc. Dis.,34, No 2, 101–112 (1991).PubMedCrossRefGoogle Scholar
  7. 7.
    A. E. Elliott,Statistical Data Analysis for IBM PC and Compatible Computers, Houston (1990).Google Scholar
  8. 8.
    V. Fleury, S. Loyau, H. R. Lijnen,et al. Eur. J. Biochem.,216, 549–556 (1993).PubMedCrossRefGoogle Scholar
  9. 9.
    V. Gurevich,Semin. Thromb. Hemost,15, No 2, 123–128 (1989).CrossRefGoogle Scholar
  10. 10.
    J. Henkin, P. Marcotte, and H. Yang,Progr. Cardiovasc. Dis.,34, No 2, 135–164 (1991).CrossRefGoogle Scholar
  11. 11.
    P. Holvoet, M. Dewerchin, J. M. Stassen,et al., Circulation,87, No 3, 1007–1016 (1993).PubMedGoogle Scholar
  12. 12.
    R. E. Klabunde, C. C. Hemenway, S. J. Mohrgan,et al., Thromb. Res.,50, 857–864 (1988).PubMedCrossRefGoogle Scholar
  13. 13.
    A. V. Maksimenko, M. B. Samarenko, A. D. Petrov,et al., Ann. New York Acad. Sci.,613, 479–482 (1990).Google Scholar
  14. 14.
    A. V. Maksimenko and V. P. Torchilin,Thromb. Res.,38, 289–295 (1985).PubMedCrossRefGoogle Scholar
  15. 15.
    M. S. Runge, T. Quertermous, and E. Haber,Circulation,79, No 2, 217–224 (1989).PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • A. V. Maksimenko
    • 1
  • E. G. Tishchenko
    • 1
  • M. L. Petrova
    • 1
  • V. L. Golubykh
    • 1
  1. 1.Institute of Experimental Cardiology, Cardiology Research CenterRussian Academy of Medical SciencesMoscow

Personalised recommendations